Alnylam Pharmaceuticals, Inc.
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE

Last updated:

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA

Status:
Application
Type:

Utility

Filling date:

14 Sep 2021

Issue date:

4 Aug 2022